American Journal of Cardiovascular Drugs

, Volume 9, Issue 6, pp 393–400

Examination of the Effect of Implantable Cardioverter-Defibrillators on Health-Related Quality of Life

Based on Results from the Multicenter Automatic Defibrillator Trial-II
  • Katia Noyes
  • Ethan Corona
  • Peter Veazie
  • Andrew W. Dick
  • Hongwei Zhao
  • Arthur J. Moss
Original Research Article



While implantable cardioverter-defibrillators (ICDs) improve survival, their benefit in terms of health-related quality of life (HRQOL) is negligible.


To examine how shocks and congestive heart failure (CHF) mediate the effect of ICDs on HRQOL.


The US patients from the MADIT-II (Multicenter Automatic Defibrillator Trial-II) trial (n = 983) were randomized to receive an ICD or medical treatment only. HRQOL was assessed using the Health Utility Index 3 at baseline and 3, 12, 24, and 36 months following randomization. Logistic regressions were used to test for the effect of ICDs on the CHF indicator, and linear regressions were used to examine the effect of ICD shocks and CHF on HRQOL in living patients. We used a Monte Carlo simulation and a parametric Weibull distribution survival model to test for the effect of selective attrition. Observations were clustered by patients and robust standard errors (RSEs) were used to control for the non-independence of multiple observations provided by the same patient.


Patients in the ICD arm had 41% higher odds of experiencing CHF since their last assessment compared with those in the control arm (RSE = 0.19, p = 0.01). Developing CHF reduced HRQOL at the subsequent visit by 0.07 (p<0.01). Having ICD shocks reduced overall HRQOL by 0.04 (p = 0.04) at the subsequent assessment. The negative effect of ICD firing on HRQOL was an order of magnitude greater than the effect of CHF.


A higher prevalence of CHF and shocks among patients with ICDs and their negative effect on HRQOL may partially explain the lack of HRQOL benefit of ICD therapy.


  1. 1.
    Agency for Healthcare Research and Quality. HCUPnet [online]. Available from URL: [Accessed 2009 Sep 22].
  2. 2.
    Noyes K, Corona E, Zwanziger J, et al. Quality of life and economic consequences of implantable cardiac defibrillator: results from MADIT II. Medical Care 2007; 45(5): 377–85.PubMedCrossRefGoogle Scholar
  3. 3.
    Moss AJ, Zareba W, Hall WJ, etal. Prophylactic implantation ofadefibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346(12): 877–83.PubMedCrossRefGoogle Scholar
  4. 4.
    Leplege A, Hunt S. The problem of quality oflifeinmedicine. JAMA 1997; 278: 47–50.PubMedCrossRefGoogle Scholar
  5. 5.
    Testa MA, Simonson DC. Assesment of quality-of-life outcomes. N Engl J Med 1996 Mar 28; 334(13): 835–40.PubMedCrossRefGoogle Scholar
  6. 6.
    Gold MR, Siegel J, Russell L, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996.Google Scholar
  7. 7.
    Sola CL, Bostwick JM. Implantable cardioverter-defibrillators induced anxiety, and quality of life. Mayo Clin Proc 2005; 80(2): 232–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Dunbar SB, Warner CD, Purcell JA. Internal cardioverter defibrillator device discharge: experiences of patients and family members. Heart Lung 1993; 22(6): 494–501.PubMedGoogle Scholar
  9. 9.
    Sears SE, Conti JB. Understanding implantable cardioverter defibrillator shocks and storms: medical and psychosocial considerations for research and clinical care. Clin Cardiol 2003; 26(3): 107–11.PubMedCrossRefGoogle Scholar
  10. 10.
    Carroll DL, Hamilton GA. Quality of life in implanted cardioverter defibrillator recipients: the impact of a device shock. Heart Lung 2005; 34(3): 169–78.PubMedCrossRefGoogle Scholar
  11. 11.
    Wallace RL, Sears SF, Lewis TS, et al. Predictors of quality of life in long-term recipients of implantable cardioverter defibrillators. J Cardiopulm Rehabil 2002; 22: 278–81.PubMedCrossRefGoogle Scholar
  12. 12.
    Goldenberg I, Moss AJ, Hall WJ, et al. Causes and consequences of heart failure after prophylactic implantation of a defibrillator in the Multicenter Automatic Defibrillator Implantation Trial II. Circulation 2006; 113: 2810–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Bryant J, Brodin H, Loveman E, et al. Clinical effectiveness and cost-effectiveness of implantable cardioverter defibrillators for arrhythmias: a systematic review and economic evaluation. Int J Technol Assess Health Care 2007; 23(1): 63–70.PubMedCrossRefGoogle Scholar
  14. 14.
    Zwanziger J, Hall WJ, Dick AW, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol 2006; 47(11): 2310–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Daubert JP, Zareba W, Hall WJ, et al. Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in Multicenter Automatic Defibrillator Implantation Trial (MADIT) II patients. J Am Coll Cardiol 2006; 47(1): 98–107.PubMedCrossRefGoogle Scholar
  16. 16.
    Furlong WJ, Feeny DH, Torrance GW, et al. The health utilities index (HUI) system for assessing health-related quality of life in clinical studies. Ann Med 2001 Jul; 33(5): 375–84.PubMedCrossRefGoogle Scholar
  17. 17.
    Noyes K, Dick AW, Holloway RG. Dynamic changes in cost-effectiveness: comparing pramipexole and levodopa in early Parkinson’s disease. Pharmacoeconomics 2005; 23(12): 1257–70.PubMedCrossRefGoogle Scholar
  18. 18.
    Engels JMPD. Imputation of missing longitudinal data: a comparison of methods. J Clin Epi 2003; 56: 968–76.CrossRefGoogle Scholar
  19. 19.
    Kahneman D. Determinants of health economic decisions in actual practice: the role of behavioral economics. Value Health 2006; 9: 65–7.CrossRefGoogle Scholar
  20. 20.
    de Lissovoy G. The implantable cardiac defibrillator: is the glass half empty or half full? Med Care 2007; 45(5): 371–3.PubMedCrossRefGoogle Scholar
  21. 21.
    Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006; 114: 135–42.PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Katia Noyes
    • 1
  • Ethan Corona
    • 1
  • Peter Veazie
    • 1
  • Andrew W. Dick
    • 2
  • Hongwei Zhao
    • 3
  • Arthur J. Moss
    • 4
  1. 1.Department of Community and Preventive MedicineUniversity of RochesterRochesterUSA
  2. 2.The RAND CorporationPittsburghUSA
  3. 3.Biostatistics and Computational BiologyUniversity of Rochester Medical CenterRochesterUSA
  4. 4.Department of MedicineUniversity of Rochester Medical CenterRochesterUSA

Personalised recommendations